SERINA THERAPEUTICS INC.(NYSEARCA:SER) stock News

SER Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors

3 days ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s Disease

a month ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease

a month ago - By: Serina Therapeutics, Inc.

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

a month ago - By: Benzinga - Mentions: CGC CASI FBIO AQB ...

12 Health Care Stocks Moving In Friday's After-Market Session

a month ago - By: Stocktwits

Why Did Serina Therapeutics Stock Rocket 37% After The Bell Today?

a month ago - By: Benzinga - Mentions: EPIX LPTX MOLN NBTX ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

2 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson’s Disease under 505(b)(2) NDA Pathway

2 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

2 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

2 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference

3 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

3 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

4 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

4 months ago - By: Serina Therapeutics, Inc.

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

4 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

4 months ago - By: Serina Therapeutics, Inc.

Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

5 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

5 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

5 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

5 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

6 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

6 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

6 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

7 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

7 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

8 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

8 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

9 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Announces Sale of UniverXome Subsidiary

9 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

10 months ago - By: Serina Therapeutics, Inc.

Serina Therapeutics to Present at Tribe Public’s Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

10 months ago - By: Serina Therapeutics, Inc.

SERINA THERAPEUTICS INC. (SER) Stock News

SER Latest News, Press Relases and Analysis

Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors

Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s Disease

Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease

Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

12 Health Care Stocks Moving In Friday's After-Market Session

Why Did Serina Therapeutics Stock Rocket 37% After The Bell Today?

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson’s Disease under 505(b)(2) NDA Pathway

Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference

Serina Therapeutics Makes Grant to New Employee Under Inducement Plan

Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42

Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42

Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?"

Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan

Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit

Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease

Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference

Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting

Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients

Serina Therapeutics Announces Sale of UniverXome Subsidiary

Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors

Serina Therapeutics to Present at Tribe Public’s Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024

Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit